Abstract Details

Title Sleep Architecture and Neurobehavioral and Cognitive Functioning in Children with Autistic Spectrum Disorders

Topic Child Neurology/Developmental Neurobiology

Presentation(s) P03 - (-)

Poster/Presentation
Number 011

Objective

Background BACKGROUND: Children with ASDs have been reported to have abnormal sleep architecture but it is unclear if these findings influence daytime affect, behavior, and/or cognition.

Design/Methods DESIGN/METHODS: We collected a single night of home polysomnography from 15 children with ASDs and 20 children with TD, ages 9-18 years, matched for age and non-verbal IQ. We compared groups' total sleep time (TST), sleep onset latency (SOL), sleep efficiency (SE), wakefulness after sleep onset (WASO) and percentage of sleep stages. Correlations between sleep parameters and results on the Child Behavior Checklist (CBCL), Differential Abilities Scales Test and Delis-Kaplan Executive Function tests were calculated for each group.

Results RESULTS: Children with ASD had longer SOL (means: ASD 39.8 min, TD 16.5 min, p=0.002), reduced SE (ASD 85.7%, TD 91.6%, p=0.004), and increased WASO (ASD 49.0 min, TD 28.0 min, p=0.04) compared to controls. Groups did not differ significantly on sleep stage percentages. ASD children had higher T-scores for affective problems on the CBCL than TD group (ASD 63.7, TD 51.7, p<0.0001); however, only the TD group demonstrated correlations between total affective problems and TST (TD r= -0.53, p=0.02; ASD r= -0.23, p=0.4), REM sleep (TD r= -0.48, p=0.03; ASD r= -0.18, p=0.5;) and slow wave sleep percentages (TD r= -0.45, p=0.04; ASD r= 0.15, p=0.6;). Neither group demonstrated correlations between sleep stage percentages and cognitive test scores.

Conclusions CONCLUSIONS: Children with ASDs have more disturbed sleep and affective problems than TD children. Affective problems improve with increased sleep, particularly REM and slow wave sleep, in TD children, but not in children with ASDs. Further investigation is needed on the microarchitectural differences of sleep that may influence emotional modulation in children with ASDs.

Authors/Disclosures
Kiran P. Maski, MD (Boston Children'S Hospital) PRESENTER	An immediate family member of Dr. Maski has received personal compensation for serving as an employee of Sanofi Genzyme. Dr. Maski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Harmony Biosciences. Dr. Maski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alkermes. Dr. Maski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Maski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Maski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for KemPharm. Dr. Maski has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Idorsia. Dr. Maski has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Hayes Legal Services. An immediate family member of Dr. Maski has stock in Sanofi Genzyme. The institution of Dr. Maski has received research support from Jazz Pharmaceuticals. The institution of Dr. Maski has received research support from NIH 5K23NS104267-2. The institution of Dr. Maski has received research support from Coverys. Dr. Maski has received publishing royalties from a publication relating to health care.
	No disclosure on file
Dara S. Manoach, MD (Beth Israel Hospital)	The institution of Dr. Manoach has received research support from NIMH. The institution of Dr. Manoach has received research support from MGH ECOR.
	No disclosure on file
	No disclosure on file
Edward Fox, MD, PhD, FAAN	Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharmaceuticals. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Fox has received research support from Biogen. The institution of Dr. Fox has received research support from Genentech. The institution of Dr. Fox has received research support from Celgene - BMS. The institution of Dr. Fox has received research support from Chugai. The institution of Dr. Fox has received research support from Novartis. The institution of Dr. Fox has received research support from EMD-Serono. The institution of Dr. Fox has received research support from TG Therapeutics. The institution of Dr. Fox has received research support from AbbVie. The institution of Dr. Fox has received research support from Sanofi Genzyme. The institution of Dr. Fox has received research support from AbbVie.

��ɫ��

��ɫ��